Rapid Micro Biosystems (RPID) Cash & Equivalents (2020 - 2026)

Rapid Micro Biosystems' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $13.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 13715.0% year-over-year to $13.8 million; the TTM figure through Mar 2026 stood at $13.8 million (up 13715.0% YoY), while the FY2025 annual figure was $100000.0, down 50.0% from the prior year.
• Cash & Equivalents came in at $13.8 million for Q1 2026 at Rapid Micro Biosystems, up from $100000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $62.5 million in Q1 2022 to a low of $100000.0 in Q1 2023.
• A 5-year average of $15.6 million and a median of $13.8 million in 2026 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 99.89% in 2022 and jumped 22333.0% in 2024, its largest moves.
• Rapid Micro Biosystems' Cash & Equivalents stood at $200000.0 in 2022, then soared by 12042.5% to $24.3 million in 2023, then slumped by 99.18% to $200000.0 in 2024, then sank by 50.0% to $100000.0 in 2025, then soared by 13715.0% to $13.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $13.8 million, $100000.0, and $18.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison